BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 6980702)

  • 1. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.
    Gomi K; Morimoto M; Nomoto K
    Cancer Res; 1982 Oct; 42(10):4197-202. PubMed ID: 6980702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of surgical removal and effect of levamisole on cytotoxic T-cell-mediated antitumor immunity in mice.
    Gomi K; Morimoto M; Nomoto K
    Cancer Res; 1983 Nov; 43(11):5120-5. PubMed ID: 6604572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of levamisole on methylcholanthrene-induced tumor. I. Its antitumor effect and immunological mechanism].
    Gomi K; Morimoto M; Nomoto K
    Gan To Kagaku Ryoho; 1982 Jul; 9(7):1262-8. PubMed ID: 7184454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of levamisole on methylcholanthrene-induced tumor. II. Potentiation of cytotoxic T-cell activities].
    Gomi K; Morimoto M; Nomoto K
    Gan To Kagaku Ryoho; 1982 Jul; 9(7):1269-76. PubMed ID: 6985196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Nocardia rubra cell wall skeleton on T-cell-mediated cytotoxicity in mice bearing syngeneic sarcoma.
    Kawase I; Uemiya M; Yoshimoto T; Ogura T; Hirao F; Yamamura Y
    Cancer Res; 1981 Feb; 41(2):660-6. PubMed ID: 6969630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
    Evans R; Duffy T
    J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antitumor effect of a novel antitumor compound, NC-190, in the double grafted tumor system].
    Ebina T; Shishido K; Murata K
    Gan To Kagaku Ryoho; 1990 Jul; 17(7):1345-50. PubMed ID: 2369138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked reduction of subcutaneous tumor growth by intraperitoneal administration of recombinant human interleukin 2 with a cell accumulator, proteose-peptone, in mice.
    Tanida S; Uchida H; Taniguchi K; Nomoto K
    Cancer Res; 1989 Jan; 49(2):284-8. PubMed ID: 2783379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
    Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Activation and regulation of macrophages induced by inoculation of cryodestroyed tumor cells].
    Tsujino M
    Osaka Daigaku Shigaku Zasshi; 1990 Jun; 35(1):180-205. PubMed ID: 2135404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antitumor effect of Cepharanthin in the double grafted tumor system].
    Ebina T; Ishikawa K; Murata K
    Gan To Kagaku Ryoho; 1990 Jun; 17(6):1165-71. PubMed ID: 2350192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation of tumor immunity against syngeneic tumors in mice by beta-carotene.
    Tomita Y; Himeno K; Nomoto K; Endo H; Hirohata T
    J Natl Cancer Inst; 1987 Apr; 78(4):679-81. PubMed ID: 3470543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
    Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N
    Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.
    Naruo KI; Hinuma S; Shiho O; Houkan T; Ootsu K; Tsukamoto K
    Clin Exp Immunol; 1989 May; 76(2):278-83. PubMed ID: 2788049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Essential requirement of I-A region-identical host bone marrow or bone marrow-derived cells for tumor neutralization by primed L3T4+ T cells.
    Ozawa H; Iwaguchi T; Kataoka T
    J Immunol; 1987 Dec; 139(11):3896-901. PubMed ID: 2960743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts.
    Shimizu J; Zou JP; Ikegame K; Katagiri T; Fujiwara H; Hamaoka T
    J Immunol; 1991 Mar; 146(5):1708-14. PubMed ID: 1993850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of host resistance against tumors by glycyrrhizin, an active component of licorice roots.
    Suzuki F; Schmitt DA; Utsunomiya T; Pollard RB
    In Vivo; 1992; 6(6):589-96. PubMed ID: 1296807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirements for T cells in alloantigen-induced generation of non-T cell-mediated cytotoxicity against syngeneic mouse sarcoma cells.
    Paciucci PA; Macphail S; Bach FH; Zarling JM
    J Immunol; 1980 Jul; 125(1):36-9. PubMed ID: 6155401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral administration of Chlorella vulgaris augments concomitant antitumor immunity.
    Tanaka K; Tomita Y; Tsuruta M; Konishi F; Okuda M; Himeno K; Nomoto K
    Immunopharmacol Immunotoxicol; 1990; 12(2):277-91. PubMed ID: 2229925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.